Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Cardiovascular Risk and Outcomes in Patients With Cancer: The TRACE-Cancer Study (TRACE-Cancer)

13. November 2026 aktualisiert von: First Affiliated Hospital Xi'an Jiaotong University

Cardiovascular Risk Stratification, Clinical Outcomes, and Prevention in Patients With Cancer: A Nationwide Multicenter Retrospective and Prospective Cohort Study

The goal of this observational study is to investigate cardiovascular risks and long-term outcomes in adults with cancer in China. The main questions it aims to answer are:What is the risk of major adverse cardiovascular events (MACE) in patients with different types of cancer and anticancer treatments?Can clinical characteristics, cardiovascular assessments, and biomarkers help predict cardiovascular events and identify high-risk patients?This nationwide, multicenter study includes both retrospective and prospective cohorts. Researchers will collect clinical information from medical records and follow participants over time to assess cardiovascular health and outcomes.Participants in the prospective cohort will undergo cardiovascular assessments and follow-up as part of their clinical care. No experimental treatments will be assigned.

Studienübersicht

Status

Noch keine Rekrutierung

Detaillierte Beschreibung

The TRACE-Cancer Study is a nationwide, multicenter, observational cohort study designed to evaluate cardiovascular risks and long-term outcomes in adults with cancer.The study includes a retrospective cohort of patients diagnosed between January 2018 and June 2026 and a prospective cohort enrolled from June 2026, with follow-up planned through December 2036.Clinical data will include cancer characteristics, anticancer treatments, cardiovascular risk factors, medical history, laboratory tests, cardiac imaging, and biomarkers. The primary outcome is major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, nonfatal stroke, and serious arrhythmias. Secondary outcomes include all-cause mortality, cancer-specific mortality, other cardiovascular complications, and changes in cardiac function.The study will also develop and validate cardiovascular risk prediction models to support early identification and prevention of cardiovascular complications in patients with cancer. All treatment decisions will follow routine clinical practice without study-assigned interventions.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

50000

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

The study population consists of adults aged 18 years or older with pathologically or cytologically confirmed malignancies receiving cancer-related care at participating medical centers across China. The study includes two cohorts: a retrospective cohort of patients diagnosed and treated between January 2018 and June 2026, and a prospective cohort enrolling eligible patients from June 2026 onward. Participants will be recruited from general hospitals, cancer centers, and cardiovascular centers. All cancer types and stages are eligible, regardless of anticancer treatment or baseline cardiovascular status. Clinical information and long-term cardiovascular outcomes will be collected using standardized procedures. Biospecimen availability is not required for enrollment.

Beschreibung

Inclusion Criteria:

  1. Adults aged 18 years or older.
  2. Patients with a pathologically or cytologically confirmed diagnosis of malignancy.
  3. Patients receiving cancer-related diagnosis, treatment, clinical assessment, or follow-up at participating centers.
  4. For the retrospective cohort, availability of traceable clinical records, including medical history, pathology reports, treatment information, or follow-up data.
  5. For the prospective cohort, provision of informed consent by the participant or legally authorized representative, in accordance with applicable ethical requirements.
  6. Availability of baseline clinical information and the ability to obtain follow-up information through clinical records, outpatient visits, hospitalization records, telephone contact, or other approved sources.

Exclusion Criteria:

  1. Inability to confirm a diagnosis of malignancy.
  2. For the retrospective cohort, insufficient essential clinical information to establish baseline status or ascertain the primary outcome.
  3. For the prospective cohort, refusal to provide informed consent when required.
  4. Duplicate enrollment of the same participant at the same center; only the first eligible record will be retained.
  5. Other circumstances determined by the investigators to prevent appropriate participation or reliable follow-up.

Additional Consideration:

Patients will not be excluded based on cancer type, cancer stage, anticancer treatment modality, pre-existing cardiovascular conditions, comorbidities, or expected survival. The availability of biological specimens is not required for enrollment, and participants without available biospecimens will remain eligible for the clinical cohort.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: OTHER

Kohorten und Interventionen

Gruppe / Kohorte
Retrospective Cohort

Adults aged 18 years or older with pathologically or cytologically confirmed malignancies who received medical care at participating centers between January 2018 and June 2026. Clinical characteristics, anticancer treatments, cardiovascular risk factors, and long-term outcomes will be collected retrospectively from existing medical records and available follow-up data.

Prospective Cohort

Adults aged 18 years or older with pathologically or cytologically confirmed malignancies who are prospectively enrolled at participating centers beginning in June 2026. Clinical characteristics, anticancer treatments, cardiovascular assessments, and outcomes will be collected at baseline and during longitudinal follow-up through December 2036.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time to First Major Adverse Cardiovascular Event (MACE)
Zeitfenster: From baseline to the first qualifying event or the end of follow-up, up to 10 years.

Time from baseline to the first occurrence of a major adverse cardiovascular event (MACE), defined as a composite of cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, nonfatal ischemic or hemorrhagic stroke, or serious arrhythmia. Serious arrhythmias include sustained ventricular tachycardia, ventricular fibrillation, resuscitated cardiac arrest, arrhythmias requiring electrical cardioversion or defibrillation, severe bradyarrhythmias requiring permanent pacemaker implantation, and clinically significant new-onset atrial fibrillation or atrial flutter associated with hemodynamic compromise. The first qualifying event will be identified through medical records and follow-up information and adjudicated according to standardized diagnostic criteria.

From baseline to the first qualifying event or the end of follow-up, up to 10 years.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time to All-Cause Mortality
Zeitfenster: From baseline to death or the end of follow-up, up to 10 years.

Time from baseline to death from any cause. Death events and dates will be identified using hospital medical records, available death registration information, and follow-up records. The cumulative incidence and time to all-cause mortality will be assessed during follow-up.

From baseline to death or the end of follow-up, up to 10 years.
Time to Cancer-Specific Mortality
Zeitfenster: From baseline to cancer-related death or the end of follow-up, up to 10 years.

Time from baseline to death attributed to the underlying malignancy or cancer-related complications. Cancer-specific mortality will be determined based on available medical records, documented causes of death, and follow-up information. Deaths from other causes will be treated as competing events in the analysis of cancer-specific mortality.

From baseline to cancer-related death or the end of follow-up, up to 10 years.
Time to Cardiovascular Death
Zeitfenster: From baseline to cardiovascular death or the end of follow-up, up to 10 years.

Time from baseline to death attributed to cardiovascular causes, including fatal myocardial infarction, heart failure, stroke, sudden cardiac death, or other cardiovascular conditions. Cardiovascular death will be determined using available medical records, documented causes of death, and standardized adjudication criteria. Noncardiovascular deaths will be treated as competing events.

From baseline to cardiovascular death or the end of follow-up, up to 10 years.
Time to First Nonfatal Myocardial Infarction
Zeitfenster: From baseline to the first nonfatal myocardial infarction or the end of follow-up, up to 10 years.

Time from baseline to the first nonfatal myocardial infarction during follow-up. Myocardial infarction will be identified from clinical records and hospitalization data and confirmed according to standardized diagnostic criteria, including clinical presentation, cardiac troponin measurements, electrocardiographic findings, and available cardiac imaging or coronary angiographic evidence.

From baseline to the first nonfatal myocardial infarction or the end of follow-up, up to 10 years.
Time to First Hospitalization for Heart Failure
Zeitfenster: From baseline to the first hospitalization for heart failure or the end of follow-up, up to 10 years.

Time from baseline to the first hospitalization for newly diagnosed or worsening heart failure requiring inpatient treatment. Heart failure events will be identified through hospitalization records and confirmed using clinical symptoms, signs, cardiac imaging findings, laboratory results, and standardized diagnostic criteria.

From baseline to the first hospitalization for heart failure or the end of follow-up, up to 10 years.
Time to First Nonfatal Stroke
Zeitfenster: From baseline to the first nonfatal stroke or the end of follow-up, up to 10 years.

Time from baseline to the first nonfatal stroke, including ischemic and hemorrhagic stroke. Stroke events will be identified through clinical records, hospitalization data, and available neuroimaging findings and confirmed according to standardized diagnostic criteria.

From baseline to the first nonfatal stroke or the end of follow-up, up to 10 years.
Time to First Serious Arrhythmia
Zeitfenster: From baseline to the first qualifying serious arrhythmia or the end of follow-up, up to 10 years.

Time from baseline to the first occurrence of a serious arrhythmia, including sustained ventricular tachycardia, ventricular fibrillation, resuscitated cardiac arrest, arrhythmias requiring electrical cardioversion or defibrillation, severe bradyarrhythmias requiring permanent pacemaker implantation, and clinically significant new-onset atrial fibrillation or atrial flutter associated with hemodynamic compromise. Events will be identified through electrocardiograms, ambulatory electrocardiographic monitoring, implanted cardiac device records, hospitalization records, and clinical documentation.

From baseline to the first qualifying serious arrhythmia or the end of follow-up, up to 10 years.

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Plasma N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentration
Zeitfenster: Baseline and available follow-up assessments through 10 years.

Change in plasma NT-proBNP concentration from baseline to follow-up, measured using validated clinical laboratory immunoassays and reported in pg/mL. Absolute changes in NT-proBNP concentration will be calculated among participants with available baseline and follow-up measurements. Exploratory analyses will examine the relationship between NT-proBNP levels and cardiovascular outcomes, particularly heart failure events, in participants with available clinical data and biospecimens.

Baseline and available follow-up assessments through 10 years.
Change in Circulating Cardiac Troponin Concentration
Zeitfenster: Baseline and available follow-up assessments through 10 years.

Change in circulating cardiac troponin concentration from baseline to follow-up, measured using validated clinical laboratory cardiac troponin assays and reported in assay-specific concentration units. Absolute changes will be evaluated among participants with available baseline and follow-up measurements. Exploratory analyses will investigate the relationship between circulating cardiac troponin concentrations and cardiovascular outcomes, particularly myocardial injury and major adverse cardiovascular events.

Baseline and available follow-up assessments through 10 years.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Guoliang Li, First Affiliated Hospital Xi'an Jiaotong University
  • Hauptermittler: Tao Shi, First Affiliated Hospital Xi'an Jiaotong University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

11. November 2026

Primärer Abschluss (Geschätzt)

1. Dezember 2036

Studienabschluss (Geschätzt)

1. Dezember 2036

Studienanmeldedaten

Zuerst eingereicht

8. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. November 2026

Zuerst gepostet (Tatsächlich)

16. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

13. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren